key: cord-0723184-fef1k8ed
authors: Wang, Jitao; Hou, Zhiyun; Liu, Jianxin; Gu, Ye; Wu, Yunhong; Chen, Zhenhuai; Ji, Jiansong; Diao, Shiqi; Qiu, Yuanwang; Zou, Shengqiang; Zhang, Aiguo; Zhang, Nina; Wang, Fengxian; Li, Xue; Wang, Yan; Liu, Xing; Lv, Cheng; Chen, Shubo; Liu, Dengxiang; Ji, Xiaolin; Liu, Chao; Ren, Tao; Sun, Jingwei; Zhao, Zhongwei; Wu, Fazong; Li, Fenxiang; Wang, Ruixu; Yan, Yan; Zhang, Shiliang; Ge, Guohong; Shao, Jiangbo; Yang, Shiying; Liu, Chuan; Huang, Yifei; Xu, Dan; Li, Xiaoguo; Ai, Jingwen; He, Qing; Zheng, Ming-Hua; Zhang, Liting; Xie, Qing; Rockey, Don C.; Fallowfield, Jonathan A.; Zhang, Wenhong; Qi, Xiaolong
title: Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study
date: 2021-04-24
journal: J Hepatol
DOI: 10.1016/j.jhep.2021.04.026
sha: 48f899515d49bdb4ddf0079508396cbff2401e00
doc_id: 723184
cord_uid: fef1k8ed

BACKGROUND & AIMS: The development of COVID-19 vaccines has progressed with encouraging safety and efficacy data. Concerns have been raised about SARS-CoV-2 vaccine responses in the large population of patients with non-alcoholic fatty liver disease (NAFLD). The study aimed to explore the safety and immunogenicity of COVID-19 vaccination in NAFLD. METHODS: This multicenter study included patients with NAFLD without a history of SARS-CoV-2 infection. All patients were vaccinated with 2 doses of inactivated vaccine against SARS-CoV-2. The primary safety outcome was the incidence of adverse reactions within 7 days after each injection and overall incidence of adverse reactions within 28 days, and the primary immunogenicity outcome was neutralizing antibody response at least 14 days after the whole-course vaccination. RESULTS: A total of 381 patients with pre-existing NAFLD were included from 11 designated centers in China. The median age was 39.0 years (IQR 33.0–48.0 years) and 179 (47.0%) were male. The median BMI was 26.1 kg/m(2) (IQR 23.8–28.1 kg/m(2)). The number of adverse reactions within 7 days after each injection and adverse reactions within 28 days totaled 95 (24.9%) and 112 (29.4%), respectively. The most common adverse reactions were injection site pain in 70 (18.4%), followed by muscle pain in 21 (5.5%), and headache in 20 (5.2%). All adverse reactions were mild and self-limiting, and no grade 3 adverse reactions were recorded. Notably, neutralizing antibodies against SARS-CoV-2 were detected in 364 (95.5%) patients with NAFLD. The median neutralizing antibody titer was 32 (IQR 8-64), and the neutralizing antibody titers were maintained. CONCLUSIONS: The inactivated COVID-19 vaccine appears to be safe with good immunogenicity in patients with NAFLD. LAY SUMMARY: The development of vaccines against coronavirus disease 2019 (COVID-19) has progressed rapidly, with encouraging safety and efficacy data. This study now shows that the inactivated COVID-19 vaccine appears to be safe with good immunogenicity in the large population of patients with non-alcoholic fatty liver disease.

Background & Aims: The development of COVID-19 vaccines has progressed with encouraging safety and efficacy data. Concerns have been raised about SARS-CoV-2 vaccine responses in the large population of patients with non-alcoholic fatty liver disease (NAFLD). The study aimed to explore the safety and immunogenicity of COVID-19 vaccination in NAFLD. Methods: This multicenter study included patients with NAFLD without a history of SARS-CoV-2 infection. All patients were vaccinated with 2 doses of inactivated vaccine against SARS-CoV-2. The primary safety outcome was the incidence of adverse reactions within 7 days after each injection and overall incidence of adverse reactions within 28 days, and the primary immunogenicity outcome was neutralizing antibody response at least 14 days after the whole-course vaccination. Results: A total of 381 patients with pre-existing NAFLD were included from 11 designated centers in China. The median age was 39.0 years (IQR 33.0-48.0 years) and 179 (47.0%) were male.

The median BMI was 26.1 kg/m 2 (IQR 23.8-28.1 kg/m 2 ). The number of adverse reactions within 7 days after each injection and adverse reactions within 28 days totaled 95 (24.9%) and 112 (29.4%), respectively. The most common adverse reactions were injection site pain in 70 (18.4%), followed by muscle pain in 21 (5.5%), and headache in 20 (5.2%). All adverse reactions were mild and self-limiting, and no grade 3 adverse reactions were recorded. Notably, neutralizing antibodies against SARS-CoV-2 were detected in 364 (95.5%) patients with NAFLD. The median neutralizing antibody titer was 32 (IQR 8-64), and the neutralizing antibody titers were maintained. Conclusions: The inactivated COVID-19 vaccine appears to be safe with good immunogenicity in patients with NAFLD. Lay summary: The development of vaccines against coronavirus disease 2019 (COVID-19) has progressed rapidly, with encouraging safety and efficacy data. This study now shows that the inactivated COVID-19 vaccine appears to be safe with good immunogenicity in the large population of patients with nonalcoholic fatty liver disease.

Coronavirus disease 2019 (COVID-19) has caused a devastating global pandemic since early 2020. 1, 2 We read with interest the recent article by Cornberg et al., 1 in which they summarized the data on vaccine safety, immunogenicity, and efficacy in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines has progressed at an unprecedented rate with encouraging safety and efficacy data emerging from clinical trials. [3] [4] [5] Despite the large number of clinical trials of COVID-19 vaccines, only a few participants with pre-existing liver diseases were included. 1,6 Concerns have been raised recently about SARS-CoV-2 vaccine responses in the large population of patients with non-alcoholic fatty liver disease (NAFLD), 1,6,7 who may be uniquely susceptible to COVID-19 infection and disease progression. [8] [9] [10] The study aimed to explore the safety and immunogenicity of COVID-19 vaccination in patients with NAFLD in a large Chinese cohort.

This multicenter study included patients with NAFLD without a history of SARS-CoV-2 infection, from 11 designated centers in the network of Chinese Portal Hypertension Alliance (CHESS) between 4 October 2020 and 26 February 2021, with a final follow-up on March 18, 2021. NAFLD was diagnosed by liver biopsy and/or clinical findings. All patients were vaccinated with 2 doses (0.5 ml/dose) of inactivated vaccine against SARS-CoV-2 (Beijing Institute of Biological Products Co., Ltd.). Blood samples were collected at least 14 days after the whole-course vaccination. Neutralizing antibodies were detected by magnetic particle chemiluminescence immunoassay using SARS-CoV-2 neutralizing antibody detection kit (Beijing Hotgen Biotech Co., Ltd.). The primary safety outcome was the incidence of adverse reactions within 7 days after each injection and the overall incidence of adverse reactions within 28 days, and the primary immunogenicity outcome was neutralizing antibody response at least 14 days after the whole-course vaccination. Continuous variables were presented as median (IQR), and categorical variables were presented as n (%). The study was approved by the ethics committees of participating centers.

A total of 381 patients with pre-existing NAFLD were included in the analysis. The median age was 39.0 years (IQR 33.0-48.0 years) and 179 (47.0%) were male. The median BMI was 26.1 kg/ m 2 (IQR 23.8-28.1 kg/m 2 ). Of these, 348 (91.3%) patients were of Han ethnicity. Comorbidities other than NAFLD were present in 53 (13.9%) patients, consisting of 42 (11.0%) hypertension, 14 (3.7%) diabetes, 4 (1.0%) arrhythmia and 1 (0.3%) asthma. Baseline characteristics are summarized in Table 1 .

The number of adverse reactions within 7 days after each injection and adverse reactions within 28 days totaled 95 (24.9%) and 112 (29.4%) of patients, respectively. The most common adverse reactions were 70 (18.4%) injection site pain, followed by 21 (5.5%) muscle pain, 20 (5.2%) headache, and 18 (4.7%) fatigue. All adverse reactions were mild and self-limiting, and no grade 3 adverse reactions were recorded. The median interval between the completion of whole-course vaccination and the detection of neutralizing antibodies was 39.0 days (IQR, 35.0-50.0 days). Notably, neutralizing antibodies against SARS-CoV-2 were detected in 364 (95.5%) patients with NAFLD. The median neutralizing antibody titer was 32 (IQR 8-64). The adverse reactions and immunogenicity outcomes of COVID-19 vaccination in patients with NAFLD are shown in Table 2 . According to the locally weighted scatterplot smoothing, the neutralizing antibody titers were maintained over the time since wholecourse vaccination (Fig. 1 ).

This multicenter study showed that COVID-19 vaccination appeared to be safe and effective in patients with NAFLD. There 4, 5 Similar to the general population, side effects related to the COVID-19 vaccine in patients with NAFLD were mild and self-limiting, and no serious adverse events were reported. Compared to participants in the phase II trial of the same COVID-19 vaccine used in our study, 3 patients with NAFLD showed a comparable neutralizing antibody seropositivity rate after the whole-course vaccination (95.5% vs. 97.6%, respectively). More importantly, our study showed that the titers of neutralizing antibodies in patients with NAFLD persisted over time. However, our study has several limitations. First, there was a lack of baseline information on histopathological grade/ stage of NAFLD, liver function and neutralizing antibodies considering the retrospective nature of the study. Second, although the inactivated vaccine produced neutralizing antibody responses in the majority of patients with NAFLD, whether this could protect patients with NAFLD from SARS-CoV-2 infection remains unknown. A larger prospective follow-up study for robust evidence of efficacy (i.e., protection against severe disease and death) is needed. In conclusion, the inactivated COVID-19 vaccine appears to be safe with good immunogenicity in patients with NAFLD.

Abbreviations COVID-19, coronavirus disease 2019; NAFLD, non-alcoholic fatty liver disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Financial support Don C. Rockey was supported by the NIH: P30DK123703. Other authors received no financial support to produce this manuscript. 

Drafting of the manuscript: Jitao Wang. Critical revision of the manuscript for important intellectual content: Xiaolong Qi, Wenhong Zhang

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients

Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study

Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes

Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question

AASLD expert panel consensus statement: vaccines to prevent COVID-19 infection in patients with liver disease

Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study

Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis

Increased expression of key SARS-CoV-2 entry points in multiple tissues in individuals with NAFLD

The authors have declared no conflict of interest related to the study.Please refer to the accompanying ICMJE disclosure forms for further details.

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Supplementary data to this article can be found online at https:// doi.org/10.1016/j.jhep.2021.04.026.